{"entity":{"id":"ai-081","kind":"drug","name":"AI-081","aka":["Bispecific anti-PD-1/VEGF"],"tldr":"AI-081 is an experimental bispecific antibody from OncoC4 in phase 2 trials, aimed at PD-1 and VEGF / VEGFR.","summary":"AI-081 is a bispecific antibody developed by OncoC4. Its targets are PD-1 and VEGF / VEGFR (the sponsor names PD-1/VEGF). The sponsor states: dual checkpoint and angiogenesis inhibition. ClinicalTrials.gov describes the intervention as: AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06635785, plans to enrol 387 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AI-081","url":"https://clinicaltrials.gov/search?intr=AI-081"},{"label":"Sponsor page","url":"https://www.oncoc4.com/en/pipeline/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["pd1","vegf"],"drugs":[],"companies":["oncoc4"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06635785"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"dual checkpoint and angiogenesis inhibition.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ai-081/","neighbours":{"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/"}],"trial":[{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/"}]}}